hotspot -WSS

hotspot

author：leisure time 2025-10-02 20:53:12 - browse：8

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Deliver public health messages at the right time

WSS

FDA panel issues narrow recommendation for Covid vaccine booster doses

Is it ever OK for doctors to lie to their patients?

NIH trials fail to test meaningful long Covid therapies, experts say

Man killed during FBI raid in connection with threats against Biden, other officials

Emergent cuts jobs, executive role in business shake

Crowdfunding for medical bills sidesteps core problem, author says

focus

hotspot

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

AI for drug discovery: Experts on separating hype from reality

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel issues narrow recommendation for Covid vaccine booster doses

Sports medicine is finally prioritizing gender equality

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Warren pushes Witty on UnitedHealth's control over physicians

What does generative AI mean for health care? We asked experts

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Wikipedia

As billionaires fund anti

The effects of a landmark ruling on DNA ownership are becoming clearer

Chemotherapy before breast cancer surgery might fuel metastasis

Empower primary care with adequate payments and technology

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Wegovy’s successful heart trial raises vital question about weight loss

focus

focus

focus

focus